Last month, the FDA announced their approval of Amjevita, a biosimilar to AbbVie's Humira. Humira posted global sales exceeding $14 billion in 2015, and its patents are set to expire in…
So, how did we do? This year, our fifth, was very good. By all objective measures, 2015 was our most successful year, and we want to thank all…
We go to a lot of conferences. And, as a result, we see a lot of assets being marketed by pharma & biotech executives which will likely never find a…
Are you an independent consultant? Are you looking for a new platform or channel to help grow and expand your practice? Why not join us! Lacerta Bio is looking…
We’re actively seeking guest bloggers for LacertaBio.com! The ideal guest blogger: - Is currently involved in business development and licensing - Currently works for a pharma, biotech, VC, PE,…
When we studied pharmacy, compounding was in integral part of our education. On a weekly basis, we compounded just about everything: creams, lotions, elixirs, suspensions, parenterals, capsules (by hand), etc.,…
Last month, Lacerta Bio celebrated its first full year in existence. In fact, our coming out event was JP Morgan 2011. What have we learned in a year? Probably too…
As 2011 draws to a close, here are a few thoughts on 2011 and 2012: Uncertainty - If there is one word that captures the mood of the year, it…
Earlier this month, Keith Powell posed an interesting question: The economies of California and the UK are similar, as are the university networks. Why then, does California boast the most…
Lacerta Bio was fortunate to attend this year's BioPharm America conference in Boston. Here are a few of our comments and observations: Are Specialty Markets the Future? - Moderated by…